N/A
N=86
Pulmonary Function After Hyperbaric Oxygen Therapy
Oxygen Toxicity
Bottom Line
View on ClinicalTrials.gov: NCT05088772 ↗Enrolled (actual)
86
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Change in Percentage Predicted Forced Expiratory Volume in One Second (FEV1%) — 88.0; 85.9; 87.4; 84.6 Percentage of FEV1
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Hyperbaric Oxygen Therapy (Device)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- University of Toronto
- Primary completion
- Jun 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Percentage Predicted Forced Expiratory Volume in One Second (FEV1%) |
88.0; 85.9; 87.4; 84.6 | — |
| PRIMARY Change in Percentage Predicted Forced Vital Capacity (FVC%) |
88.8; 86.9; 89.2; 85.9 | — |
| PRIMARY Change in Percentage Predicted Forced Mid-Expiratory Flow Rate (FEF25-75%) |
66.9; 66.7; 66.2; 64.6 | — |
| SECONDARY Pulmonary Complications Following Hyperbaric Oxygen Therapy |
— | — |
Summary
Patients receiving hyperbaric oxygen therapy (HBOT) for any indication at the Hyperbaric Medicine Unit (University Health Network, Toronto, ON, Canada) from 2016-2021 were recruited to this prospective cohort study. While receiving HBOT (at 2.0-2.4 ATA, with 1-3 "air breaks", with specific treatment details determined on a case-by-case basis and directed by the clinical team), enrolled patients underwent pulmonary function testing prior to HBOT treatment and serially after each 20 completed treatment cycles.
Eligibility Criteria
Inclusion Criteria
- Patients scheduled to receive at least ten cycles of HBOT (for any indication)
Exclusion Criteria
- Inability to provide informed consent
Data sourced from ClinicalTrials.gov (NCT05088772). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.